Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib vs Dasatinib + BMS-833923 in Newly Diagnosed CP-CML
NCT01357655Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2011
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of BMS-833923 in chronic myeloid leukemia (CML), sponsored by Bristol Myers Squibb. Started Sep 2011; status: terminated.
02
Drugs
BMS-833923
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01357655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01357655.